Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) – Pilot trial of a phase I/II study: study protocol
2007

Pilot Study of IMRT for Ovarian Cancer

Sample size: 8 publication Evidence: low

Author Information

Author(s): Rochet Nathalie, Jensen Alexandra D, Sterzing Florian, Munter Marc W, Eichbaum Michael H, Schneeweiss Andreas, Sohn Christof, Debus Juergen, Harms Wolfgang

Primary Institution: University of Heidelberg

Hypothesis

Can intensity-modulated radiation therapy (IMRT) improve the feasibility and reduce toxicity of whole abdominal irradiation (WAI) in high-risk stage III ovarian cancer patients?

Conclusion

The study aims to evaluate the feasibility and toxicity of IMRT for whole abdominal irradiation in patients with advanced ovarian cancer.

Supporting Evidence

  • Ovarian cancer has a poor prognosis, with over 60% of patients developing recurrent disease.
  • Whole abdominal irradiation has been shown to be effective but is underused due to high toxicity.
  • IMRT may reduce toxicity while effectively treating the peritoneal cavity.

Takeaway

This study is testing a new way to give radiation therapy to help women with advanced ovarian cancer while trying to avoid hurting their healthy organs.

Methodology

Single center pilot trial of a phase I/II study treating patients with advanced ovarian cancer stage FIGO III using IMRT for whole abdominal irradiation.

Limitations

The study is limited to a small sample size of 8 patients, which may not provide conclusive evidence.

Participant Demographics

Patients aged 18 to 75 with histologically confirmed ovarian cancer stage FIGO III and specific health criteria.

Digital Object Identifier (DOI)

10.1186/1471-2407-7-227

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication